Cancer Immunotherapy Conference Agenda

Day One

 

7:30 a.m.

Registration

8:00 a.m.

Opening Remarks

8:05 a.m.

Keynote Address:
New Era in Cell Therapy: From CAR-T to Solid Tumor

 

Renier Brentjens, M.D., Ph.D.
Director-Cellular Therapies
Memorial Sloan Kettering

session i

Adoptive Cell Therapies

8:45 a.m.

Q&A

8:55 a.m.

Novel CARs and TCRs

 

Helen Tayton-Martin, Ph.D.
Chief Business Officer
Adaptimmune Therapeutics plc

Poseida Therapeutics, Inc.
Speaker to be announced

Christian Itin, Ph.D.
Chief Executive Officer and Chairman of the Board of Directors
Autolus Limited

9:40 a.m.

Q&A

9:45 a.m.

Allogenic Platforms

 

Andre Koulika, Ph.D.
Chief Executive Officer
Cellectis SA

CRISPR Therapeutics AG
Speaker to be announced

Chris Haqq, M.D., Ph.D.
Executive Vice President and Chief Scientific Officer
Atara Biotherapeutics, Inc.

10:20 a.m.

Q&A

10:25 a.m.

Coffee Break

10:40 a.m.

Other Cell Types (NK and TILs)

 

Bob Valamehr, Ph.D.
Vice President-Immunotherapy
Fate Therapeutics, Inc.

Maria Fardis, Ph.D.
Chief Executive Officer
Iovance Biotherapeutics, Inc.

11:10 a.m.

Q&A

11:15 a.m.

Safety Issues of Cell Therapies

 

David Spencer, Ph.D.
Chief Scientific Officer
Bellicum Pharmaceuticals, Inc.

11:35 a.m.

Q&A

11:40 a.m.

Cytokines

 

Deborah Charych, Ph.D.
Executive Director - Research and Development
Nektar Therapeutics

Martin Oft, M.D.
Founder and Vice President, Pre-Clinical and Clinical Development
ARMO Biosciences, Inc.

12:10 p.m.

Break

12:25 p.m.

Lunch Panel: Setting Up Commercial Cell Therapy Products
in Academic Center / Q&A

 

Sergio Giralt, M.D.
Chief, Adult Bone Marrow Transplant Service
Melvin Berlin Family Chair in Multiple Myeloma
Memorial Sloan Kettering Cancer Center

session ii

Jump Starting the Immune System

1:00 p.m.

Break

1:15 p.m.

Cancer Therapeutic Vaccines Overview

 

Col. (ret.) George E. Peoples, M.D., F.A.C.S., MC, USA
Founder and CEO, Cancer Insight, LLC;
Director-Cancer Vaccine Development Program, Metis Foundation;
Professor of Surgery, Uniformed Services University;
Professor (adjunct) of Surgical Oncology, MD Anderson Cancer Center

1:35 a.m.

Q&A

1:40 p.m.

Oncolytic Viruses

 

Oncolytic Viruses Making Tumors Hot
Robert H.I. Andtbacka, M.D., C.M., F.A.C.S., F.R.C.S.C.
Associate Professor, Surgical Oncology
Department of Surgery
University of Utah
Co-Director Melanoma Program
Co-Director Melanoma Clinical Research Program
Huntsman Cancer Institute

2:05 a.m.

Q&A

2:10 p.m.

Keynote II:
Building a Leader in Cell Therapy-Challenges Facing
Clinical and Commercial Strategies

 

Pascal Touchon, D.V.M.
Senior Vice President, Global Head-Cell and Gene
Novartis Oncology

2:55 a.m.

Q&A

3:00 p.m.

Coffee Break

3:10 p.m.

In Situ Vaccination

 

Joshua Brody, M.D.
Director-Lymphoma Immunotherapy Program
Icahn School of Medicine at Mount Sinai, Hess Center for Science
and Medicine

3:30 a.m.

Q&A

3:35 p.m.

Toll Like Receptor Agonists

 

Robert Coffman, Ph.D.
Senior Vice President and Chief Scientific Officer
Dynavax Technologies Corporation

Joanna Horobin, M.D.
Chief Medical Officer
Idera Pharmaceuticals, Inc.

4:05 a.m.

Q&A

4:10 p.m.

STING Agonists

 

Natalie Sacks, M.D.
Chief Medical Officer
Aduro Biotech, Inc

R.P. "Kris" Iyer, Ph.D.
Chief Scientific Officer
Spring Bank Pharmaceuticals

4:45 p.m.

Q&A

4:50 p.m.

Reception

Day Two

 

7:30 a.m.

Registration

8:00 a.m.

Opening Remarks

8:05 a.m.

Keynote III:
Personalized Cancer Immunotherapies

 

Ira Mellman, Ph.D.
Vice President-Cancer Immunology
Genentech, Inc.

8:50 a.m.

Q&A

Session III

Next generation approaches

8:55 a.m.

Neoantigens

 

John Castle, Ph.D.
Head-Translational Medicine and Bioinformatics
Agenus Inc.

Gritstone Oncology
Speaker to be announced

Genocea Biosciences, Inc.
Speaker to be announced

9:40 a.m.

Q&A

9:45 a.m.

Keynote IV:
Optimizing the Immune Microenvironment in Prostate Cancer

 

Ravi Madan, M.D.
Clinical Director-Genitourinary Malignancies Branch
Center for Cancer Research, National Cancer Institute

10:25 a.m.

Q&A

10:30 a.m.

Coffee Break

10:40 a.m.

Tumor Microenvironment: MDSCs and Tregs

 

The Tumor Microenvironment in Cancer: Reevaluating Checkpoints on
Suppressive Myeloid Cells

 

Catherine Sabatos-Peyton, Ph.D.
Director of Exploratory Immuno-Oncology
Novartis Institutes for Biomedical Research

 

Jeff Kutok, Ph.D.
Chief Scientific Officer
Infinity Pharmaceuticals, Inc.

11:15 a.m.

Q&A

11:20 a.m.

Tumor Microenvironment: Metabolites/Enzymes

 

Charles Link Jr. M.D.
Chief Executive Officer
NewLink Genetics Corporation

Keith Orford, M.D., Ph.D.
Senior Vice President of Clinical Development
Calithera Biosciences, Inc.

11:50 a.m.

Q&A

11:55 a.m.

Break

12:05 p.m.

Lunch Panel: Economics of Immunotherapies and
Immunotherapy Combinations

 

Bryon Wornson, moderator
Vice President-Global Health and Value
Pfizer Inc.

 

Ed Schoonveld
Managing Principal, Value
& Access ZS Associates

 

Ed Pezalla, M.D.,
Former National Medical Director for Pharmaceutical Policy and Strategy
Aetna

 

Sophie Opdyke
VP & Immuno-Oncology Lead - Global Marketing and Commercial
Development Pfizer

Session IV

Immunotherapy Combinations

1:00 p.m.

Keynote V:
Clinical Combination Strategies in Immunotherapy

 

Roger Dansey, M.D.
Senior Vice President-Global Clinical Development Oncology
Merck Research Laboratories, Merck & Co.

1:40 p.m.

Q&A

1:45 p.m.

Developing Rational Combinations in Immuno-Oncology

 

Ruslan Novosiadly, M.D., Ph.D.
Senior Research Advisor
Experimental & Translational Immunooncology
Department of Cancer Immunobiology
Eli Lilly & Company

2:05 p.m.

Q&A

2:10 p.m.

Targeted Therapy Combinations With Immunotherapy

 

Chris Boshoff, M.D., Ph.D.
Senior Vice President and Head of Immuno-Oncology, Early Development and
Translational Oncology
Pfizer Inc.

2:30 p.m.

Q&A

2:35 p.m.

Coffee Break

2:50 p.m.

Personalized Immunotherapy for NSCLC

 

Roy Hersbt, M.D., Ph.D.
Ensign Professor of Medicine (Oncology), Chief-Medical Oncology,
Associate Director-Translational Research, Director-Thoracic
Oncology Research Program
Yale Comprehensive Cancer Center, Yale School of Medicine

3:20 p.m.

Q&A

3:25 p.m.

Immunotherapy Combinations for Renal Cell or Urothelial Carcinoma

 

Andrea Apolo, M.D.
Investigator-Genitourinary Malignancies Branch, Head-Bladder
Cancer Section, NIH Lasker Clinical Research Scholar
Center for Cancer Research, NIH

3:50 p.m.

Q&A

3:55 p.m.

Microbiome in IO

 

Bruce Roberts, Ph.D.
Chief Scientific Officer
Vedanta Biosciences

J.C. Gutierrez Ramos, Ph.D.
Chief Executive Officer
Synlogic

4:25 p.m.

Q&A

4:30 p.m.

Bispecifics

 

Ton Logtenberg, Ph.D.
Chief Executive Officer
Merus N.V.

Louis Matis, M.D.
Senior Vice President and Chief Development Officer
Pieris Pharmaceuticals, Inc.

5:00 p.m.

Q&A

5:05p.m.

Reception

Speakers

 

 

Andrew Allen, M.D., Ph.D.
President and Chief Executive Officer
Gritstone Oncology

 

Robert H.I. Andtbacka, M.D., C.M., F.A.C.S., F.R.C.S.C.
Associate Professor, Surgical Oncology
Department of Surgery
University of Utah
Co-Director Melanoma Program
Co-Director Melanoma Clinical Research Program
Huntsman Cancer Institute

 

Andrea Apolo, M.D.
Investigator-Genitourinary Malignancies Branch, Head-Bladder
Cancer Section, NIH Lasker Clinical Research Scholar
Center for Cancer Research, NIH

 

Chris Boshoff, M.D., Ph.D.
Senior Vice President and Head of Immuno-Oncology, Early
Development and Translational Oncology
Pfizer Inc.

 

Renier Brentjens, M.D., Ph.D.
Director-Cellular Therapies
Memorial Sloan Kettering

 

Joshua Brody, M.D.
Director-Lymphoma Immunotherapy Program
Icahn School of Medicine at Mount Sinai, Hess Center for Science
and Medicine

 

John Castle, Ph.D.
Head-Translational Medicine and Bioinformatics
Agenus Inc.

 

Deborah Charych, Ph.D.
Executive Director - Research and Development
Nektar Therapeutics

 

Andre Choulika, Ph.D.
Chief Executive Officer
Cellectis SA

 

Chip Clark
President and Chief Executive Officer
Genocea Biosciences, Inc.

 

Robert Coffman, Ph.D.
Senior Vice President and Chief Scientific Officer
Dynavax Technologies Corporation

 

Roger Dansey, M.D.
Senior Vice President-Global Clinical Development Oncology
Merck Research Laboratories, Merck & Co.

 

Maria Fardis, Ph.D.
Chief Executive Officer
Iovance Biotherapeutics, Inc.

 

Sergio Giralt, M.D.
Chief, Adult Bone Marrow Transplant Service, Melvin Berlin
Family Chair in Multiple Myeloma
Memorial Sloan Kettering Cancer Center

 

J.C. Gutierrez Ramos, Ph.D.
Chief Executive Officer
Synlogic

 

Chris Haqq, M.D., Ph.D.
Executive Vice President and Chief Scientific Officer
Atara Biotherapeutics, Inc.

 

Roy Hersbt, M.D., Ph.D.
Ensign Professor of Medicine (Oncology), Chief-Medical Oncology,
Associate Director-Translational Research, Director-Thoracic
Oncology Research Program
Yale Comprehensive Cancer Center, Yale School of Medicine

 

Joanna Horobin, M.D.
Chief Medical Officer
Idera Pharmaceuticals, Inc.

 

Christian Itin, Ph.D.
Chief Executive Officer and Chairman of the Board of Directors
Autolus Limited

 

R.P. "Kris" Iyer, Ph.D.
Chief Scientific Officer
Spring Bank Pharmaceuticals

 

Jeff Kutok, Ph.D.
Chief Scientific Officer
Infinity Pharmaceuticals, Inc.

 

Charles Link Jr., M.D.
Chief Executive Officer
NewLink Genetics Corporation

 

Ton Logtenberg, Ph.D.
Chief Executive Officer
Merus N.V.

 

Ravi Madan, M.D.
Clinical Director-Genitourinary Malignancies Branch
Center for Cancer Research, National Cancer Institute

 

Louis Matis, M.D.
Senior Vice President and Chief Development Officer
Pieris Pharmaceuticals, Inc.

 

Ira Mellman, Ph.D.
Vice President-Cancer Immunology
Genentech, Inc.

 

Ruslan Novosiadly, M.D., Ph.D.,
Senior Research Advisor
Experimental & Translational Immunooncology
Department of Cancer Immunobiology
Eli Lilly & Company

 

Martin Oft, M.D.
Founder and Vice President, Pre-Clinical and Clinical
Development
ARMO Biosciences, Inc.

 

Sophie Opdyke
VP & Immuno-Oncology Lead - Global Marketing and Commercial
Development Pfizer

 

Keith Orford, M.D., Ph.D.,
Senior Vice President of Clinical Development
Calithera Biosciences, Inc.

 

Col. (ret.) George E. Peoples, M.D., FACS, MC, USA, Col. (ret.)
George E. Peoples, M.D., FACS, MC, USA

Founder and CEO, Cancer Insight, LLC; Director-Cancer Vaccine
Development Program, Metis Foundation; Professor of Surgery,
Uniformed Services University; Professor (adjunct) of Surgical
Oncology, MD Anderson Cancer Center

 

Ed Pezalla, M.D.,
Former National Medical Director for Pharmaceutical Policy and
Strategy, Aetna

 

Thomas Potts Director
Global Pricing
Bristol-Myers Squibb
Interim CODE Lead

 

Bruce Roberts, Ph.D.
Chief Scientific Officer
Vedanta Biosciences

 

Catherine Sabatos-Peyton, Ph.D.
Director of Exploratory Immuno-Oncology
Novartis Institutes for Biomedical Research

 

Natalie Sacks, M.D.
Chief Medical Officer
Aduro Biotech, Inc

 

Ed Schoonveld
Managing Principal, Value & Access
ZS Associates

 

Devon Shedlock, Ph.D.
Vice President, Preclinical Development
Poseida Therapeutics, Inc.

 

David Spencer, Ph.D.
Chief Scientific Officer
Bellicum Pharmaceuticals, Inc.

 

Helen Tayton-Martin, Ph.D.
Chief Business Officer
Adaptimmune Therapeutics plc

 

Pascal Touchon, D.V.M.
Senior Vice President, Global Head-Cell and Gene
Novartis Oncology

 

Bob Valamehr, Ph.D.
Vice President-Immunotherapy
Fate Therapeutics, Inc.

 

Bryon Wornson
Vice President-Global Health and Value
Pfizer Inc.